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OBJECTIVES: To assess the distribution of dementia subtypes in Brazil using a population-based clinicopatho-
logical study.
METHOD: Brains from deceased individuals aged $50 years old were collected after the next of kin signed an
informed consent form and provided information through standardized questionnaires. Post-mortem clinical
diagnoses were established in consensus meetings, and only cases with moderate or severe dementia or
without cognitive impairment were included in the analysis. Immunohistochemical neuropathological
examinations were performed following the universally accepted guidelines. A diagnosis of Alzheimer’s
disease was made when there were at least both a moderate density of neuritic plaques (Consortium to
Establish a Register for Alzheimer’s disease B or C) and Braak stage III for neurofibrillary tangle distribution. For
the diagnosis of vascular dementia, at least three zones or strategic areas had to be affected by infarcts,
lacunae, or microinfarcts.
RESULTS: From 1,291 subjects, 113 cases were classified as having moderate or severe dementia, and 972 cases
were free of cognitive impairment. The neuropathological diagnoses of the dementia sub-group were
Alzheimer’s disease (35.4%), vascular dementia (21.2%), Alzheimer’s disease plus vascular dementia (13.3%),
and other causes of dementia (30.1%). Small-vessel disease, which alone was not considered sufficient for a
vascular dementia diagnosis, was present in 38.9% of all of the dementia cases and in 16.8% of the group
without cognitive impairment (odds ratio = 2.91; 95% confidence interval, 1.53-5.51), adjusted for age, sex, and
education.
CONCLUSIONS: The relatively high frequencies of vascular dementia and small-vessel disease in the dementia
sub-group constitute relevant findings for public health initiatives because control of vascular risk factors could
decrease the prevalence of dementia in developing countries.
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& INTRODUCTION
Alzheimer’s disease (AD) is considered to be the most
frequent cause of dementia in Western countries (1), but
recent studies have raised the hypothesis that vascular
dementia (VaD), either pure or associated with AD, is at
least as common as ‘‘pure’’ AD in developed countries (2,3).
It is known that almost two-thirds of individuals with
dementia live in developing countries (4), where the
risk factors for cerebrovascular disease, such as arterial
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hypertension, diabetes mellitus, and hyperlipidemia, are less
adequately detected and treated (5). Therefore, it is reason-
able to suppose that cerebrovascular disease plays a more
decisive role in developing countries than in developed
regions. Nevertheless, epidemiological studies performed in
developing regions have shownAD to be the leading cause of
dementia. In Latin America, population surveys have
indicated AD as the cause of dementia in from 49.9% to
84.5% of cases, whereas VaD was diagnosed in only 8.5% to
26.5% of the cases (6). In a broader analysis of the prevalence
of dementia in developing regions, 60% of the cases were
attributed to AD and approximately 30% to VaD (7).
However, none of these results were validated by autopsy.
Rigorous population-based clinicopathological studies
have been very difficult to perform (8). The greatest
weakness of these studies has been the use of biased
samples, usually taken from memory clinics or other non-
representative groups. Generally, this selection has resulted
in participation being skewed toward subjects with severe
dementia (8). No true population-based clinicopathological
studies of dementia have been previously conducted in a
developing country, where the factors that impact the
clinical expression of dementia, such as the mean age at
death and mean educational attainment, are different from
those in developed countries. Here, we report the distribu-
tion of dementia subtypes in a developing country,
evaluated in a population-based clinicopathological study,
and we discuss the similarities and differences between
these data and those derived from similar studies in
developed countries.
& SUBJECTS AND METHODS
Study subjects and clinical evaluation
This investigation was conducted at the Brain Bank of the
Brazilian Aging Brain Study Group (BBBABSG), which is
supplied by the Sa˜o Paulo City Autopsy Service (SPAS). The
SPAS performs approximately 13,000 autopsies per year.
The methods used by the BBBABSG have been previously
reported (9). In Sa˜o Paulo, autopsy is compulsory for those
deceased from presumed natural causes without death
certificates. All the protocols were approved by the local
ethics committee (285/04), and inclusion was conditional
upon written consent from the next of kin (9). The BBBABSG
collects brains from deceased individuals aged $50 years
old, for whom an immediate brain examination was not
required for completion of the death certificate. To be
included in the BBBABSG, the cases had to have compre-
hensive clinical information from a reliable source. In brief,
upon arrival at the SPAS, a knowledgeable informant in
close contact with the subject was invited to participate in
this study and to provide clinical and functional informa-
tion about the deceased. The interview was conducted by a
skilled team of gerontologists, trained in the application of a
series of semi-structured questionnaires that covered major
cognitive and functional domains (9).
The clinical diagnosis was made in a consensus meeting
with the participation of gerontologists and of one neurol-
ogist with expertise in dementia, using all of the available
information. At the brain bank, the diagnosis of dementia
was based on DSM-IV criteria. Additionally, to increase
specificity, only individuals with a Clinical Dementia Rating
(CDR) .0.5 and an Informant Questionnaire on Cognitive
Decline in the Elderly (IQCODE) score .3.41 (10) were
included. The CDR is a five-point scale for classifying
dementia severity, in which stage 0 corresponds to no
cognitive decline, 0.5 indicates questionable dementia, and
stages 1, 2, and 3 correspond to mild, moderate, and severe
dementia, respectively (11). To determine the clinical
dementia subtype, we used the NINCDS-ADRDA for the
diagnosis of probable and possible AD (when not associated
with cerebrovascular disease). The NINDS criteria were
used for the diagnosis of possible VaD and for AD plus
cerebrovascular disease. Other types of dementia were
diagnosed using standard diagnostic criteria (9). In the
control group, the individuals showed no signs of cognitive
impairment (CDR 0 and IQCODE #3.41).
During the study period (April 2004 to March 2007),
23,473 autopsies of individuals aged $50 years old, who
died from natural causes, were performed in the SPAS.
These subjects had a mean age of 68.3 (¡11.5) years old, and
56.7% were male. This sample represented 13.5% of the
173,635 deaths in this age group in the city of Sa˜o Paulo.
During the same period, 1,291 cases were added to the
BBBABSG, with a mean age of 68.6 (¡11.4) years old. Of
these 1,291 cases, 56.0% were male. There were no
differences between the ages or sexes of the cases included
in the study and of the total group in whom autopsies were
carried out (Student’s t-test and chi square test, respectively,
p.0.05).
The present study included all of the subjects with
moderate or severe dementia (CDR$2), plus the same
number of paired control cases, matched for age and sex,
who were electronically assigned from the control cases pool.
Tissue processing
The brain was removed from the skull, and both hemi-
spheres were cut into 1-cm coronal slabs and examined
macroscopically. From one hemisphere, 15 neurodegenera-
tive disease-related structures, plus any other macroscopi-
cally lesioned areas on both hemispheres, were sampled for
microscopic examination (9). All of the cases examined were
submitted to neuropathological examination, according to
standard protocols (9). Immunohistochemistry was per-
formed using antibodies against b-amyloid (4G8; 1/5,000;
Signet Laboratories, Dedhan, MA), phospho-tau (PHF-1; 1/
1,000; gift of Peter Davies, New York, NY), and a-synuclein
(EQV-1; 1/10,000; gift of Kenji Ueda, Tokyo, Japan). If
frontotemporal lobar degeneration with TDP-43 inclusions
(FTLD-TDP) was suspected, immunostaining for TDP-43
(1/500; ProteinTech, Chicago, IL) was performed. In cases
with undefined neuropathological diagnoses after standard
assessment, additional immunostaining for TDP-43 and
ubiquitin was performed. All of the sections were submitted
to antigenic retrieval in a steamer. The signals were detected
using the Vectastain ABC Kit (Vector Laboratories,
Burlingame, CA).
Neuropathological analyses
Neuropathological examinations were performed in a
blinded manner, and neuropathological diagnoses were
made by two experienced neuropathologists following
internationally accepted guidelines (9). The Consortium to
Establish a Register for Alzheimer’s disease (CERAD) criteria
were used to classify the b-amyloid neuritic plaque burden as
scarce, moderate, or frequent. The distribution of neurofi-
brillary tangles (NFTs) was classified according to the Braak
and Braak staging system (9). The neuropathological
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diagnosis of AD was made in cases that showed at least
Braak stage III and CERAD moderate (2). The usual
neuropathological guidelines were used for other dementias
and for Parkinson’s disease (9).
Microvascular changes were analyzed semi-quantitatively
using H&E staining in all of the sampled structures. The
presence of diffuse small-vessel disease (SVD) in the white
matter, of hippocampal sclerosis, and of lacunae, micro-
infarcts, and infarcts were registered. Cerebral amyloid
angiopathy (CAA) was verified using anti-b amyloid immu-
nostaining. The diagnosis of VaDwas made in cases with one
large chronic infarct (.1 cm) or three lacunae in strategic
areas (thalamus, frontocingular cortex, basal forebrain and
caudate, medial temporal area, and angular gyrus) (12).
SVD was diagnosed when there was widespread and at
least moderately severe SVD in three cortical regions. SVD
included small-vessel arteriosclerosis/atherosclerosis, arter-
iolosclerosis, and lipohyalinosis (13). CAA was not included
in the SVD group.
Cases were classified as positive for CAA when CAA was
found diffusely in the parenchyma of at least three different
cortical areas. In this study, SVD and pure CAA were not
considered sufficient for the diagnosis of VaD because the
literature remains unclear regarding vascular dementia
diagnosis in cases with no obvious parenchymal lesions.
Dementia cases in which SVD was the only finding were
classified as ‘‘undefined diagnosis’’.
Statistical analyses
Relative frequencies of AD, VaD, and AD+VaD were
measured as total numbers and were also divided by sex,
age, and educational level. Age and years of schooling were
divided into two groups: greater than or equal to the
median and less than the median. The chi-square test or
Fisher’s exact test, when appropriate, was used for
categorical variables. Student’s t-test was used for quanti-
tative variables. Logistic regression analysis was employed
to evaluate the association of SVD with dementia, adjusted
for age, sex, and schooling. SPSS (version 17; Statistical
Package for the Social Sciences, Chicago, IL) was employed,
and the value of significance was accepted as a p-value less
than 0.05 in two-tailed tests.
& RESULTS
Demographics and dementia subtypes
Dementia was diagnosed in 189 cases (14.6% of the 1,291
cases added to the BBBABSG collection over the collection
period), of which 131 cases had a CDR score $2. Of these
131 cases, 113 were suitable and available for processing
(113/131; 86.6%) and were included in the analyses. The
mean age was 78.9 (¡9.5) years old, and 37.2% were male.
The dementia and control group demographics are shown
in Table 1.
Neuropathological diagnosis
Neuropathological examinations confirmed that 55 sub-
jects (48.7% of the dementia group) met the criteria for AD
(Table 2). ‘‘Pure’’ AD was found in 30 of the subjects,
whereas 10 subjects had AD associated with other diseases:
Lewy body disease (LBD; five cases); argyrophilic grain
disease (AGD; four cases); and one case with Pick’s disease.
Another 15 cases met the neuropathological criteria for both
AD and VaD (13.3%).
Thirty-nine cases fulfilled the criteria for VaD (34.5%).
‘‘Pure’’ VaD was diagnosed in 21 subjects. In three subjects,
VaD was associated with other neurodegenerative diseases
(AGD in two cases and dementia with tangles in one case).
In the remaining 15 subjects, VaD was associated with AD,
as described previously.
A diagnosis of definite AD was more frequent in women,
whereas VaD was more frequent in men (Table 2). AD
associated with VaD was equally represented in both sexes.
VaD was more frequent in younger individuals, but AD
associated with VaD was more prevalent in older indivi-
duals. Definitive AD showed the same frequency in both
age groups. No difference in the relative frequencies of these
diseases was found regarding years of schooling (Table 2).
Table 1 - Means of demographic data and scores on informant questionnaires.
Total (N=113) Men (N=42) Women (N=71) p-value*
Controls
(N=113) p-value **
Age of death (years) 78.3 (9.7) 75.1 (10.5) 80.7 (7.9) 0.002{ 77.7 (8.8) 0.36{
Education (years of schooling) 3.1 (3.3) 3.3 (2.9) 2.6 (3.0) 0.246{ 3.5 (3.0) 0.12{
Caucasians (%) 47 (66.2) 31 (73.8) 81 (72.3) 0.395# 78 (70.3) 0.44#
CDR (sum of boxes) 13.1 (4.6) 15.0 (2.8) 15.8 (2.4) 0.135{ 0.08 (0.24) ,0.001{
IQCODE 4.3 (0.5) 4.5 (0.5) 4.6 (0.4) 0.275{ 3.0 (0.05) ,0.001{
Number of individuals with CDR 2/3 42/71 19/23 23/48 0.227# -
*: comparison between sexes within the dementia group.
**: comparison between the dementia and control groups.
{t-test; #: chi-square test.
CDR: Clinical Dementia Rating.
IQCODE: Informant Questionnaire on Cognitive Decline of the Elderly.
Table 2 - Relative frequencies of Alzheimer’ disease (AD),
vascular dementia (VaD), and AD associated with VaD
(AD+VaD) according to sex, age, and education.
AD VaD AD+VaD
Sex
Male 7 p= 0.002 15 p= 0.007 5 p= 0.6
Female 33 9 10
Age (years)
,80 18 p= 0.6 18 p= 0.009 3 p= 0.024*
$80 22 6 12
Years of
Schooling
,3 20 p= 0.6 11 p= 0.9 8 p= 0.7
$3 20 13 7
*Fisher’s exact test.
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Other defined causes of dementia were found in 16 cases
(14.1%). Nine of these cases had tauopathies (five had AGD,
and the other cases had Pick’s disease, progressive supra-
nuclear palsy, dementia with tangles, and unclassifiable
tauopathy). Five subjects had LBD (two also had AGD), and
two had FTLD-TDP.
In 18 cases (15.9%), the diagnosis remained undefined
following neuropathological examinations. Had widespread
SVD been considered sufficient for a diagnosis of VaD,
seven of them would have been classified as having VaD.
This classification would have increased the prevalence of
VaD from 34.5% to 40.7%. Another two cases had AD-
related neuropathology, but it was not sufficient for a formal
AD diagnosis. Of the remaining nine, review of the
informants’ reports disclosed that two of the individuals
had been heavy drinkers and might therefore have devel-
oped alcohol-associated dementia, a condition that is
difficult to diagnose neuropathologically. For the remaining
seven cases, we could not identify other causes for the
absence of neuropathological changes that would explain
dementia.
Upon neuropathological examination of the control
group, 73 (64.6%) individuals did not meet any criteria for
neurodegenerative or cerebrovascular disease. The neuro-
pathological criteria for AD were met in 19 cases (16.8%). Of
these, 14 had ‘‘pure’’ AD, and three also showed VaD
pathology. An additional four cases fulfilled the criteria for
VaD. Thirteen individuals (11.5%) had AGD, three (2.6%)
had LBD, and one (0.9%) had corticobasal degeneration.
SVD was present in 44 cases with dementia (38.9%), and
these cases were associated with infarcts in 19 cases. SVD
was present in 27.5% of the cases with the clinicopatholo-
gical diagnoses of AD, 41.7% of the cases with VaD, 60.0% of
the cases with AD plus VaD, 31.2% of the cases with other
dementias, and 50.0% of the cases with undefined clinico-
pathological diagnoses. In the control group, 19 cases
(16.8%) had SVD, which was associated with infarcts in
four of these cases. Therefore, there was a significantly
greater proportion of cases with dementia showing SVD,
compared with the controls, even after adjustment for age,
sex, and education (OR=2.91 [95% CI, 1.53-5.51]; p= 0.001)
Clinicopathological correlations
The clinical and neuropathological diagnoses are depicted
in Table 3.
The clinical diagnosis of AD (including cases with AD
and VaD pathologies) had sensitivity of 70.9% and
specificity of 44.8%. The clinical diagnosis of possible VaD
(including cases with AD pathology) had sensitivity of
43.6% and specificity of 70.3%.
& DISCUSSION
In our study, the percentage of individuals with a definite
neuropathological diagnosis of AD, including AD asso-
ciated with other diseases (except for VaD), was the lowest
(35.4% of subjects with moderate to severe dementia)
compared with other clinicopathological studies, in which
the AD prevalence ranged from 41.6% to 65% (8,12,14-19). In
contrast, the prevalence of pathologically confirmed VaD
(21.2%) and VaD associated with AD (13.3%) in our study
was at the higher end of other reported rates, which ranged
from 2.4% to 23.7% and from 4.1% to 21.6%, respectively
(8,12,14-19). Several factors could have contributed to these
differences, such as the use of different pathological criteria,
case-selection bias, and genetic and environmental differ-
ences between the populations.
The neuropathological criteria we used might have
decreased the sensitivity and increased the specificity of
AD diagnosis. Several other studies have adopted criteria
based solely on the presence of amyloid plaques, such as the
Khachaturian criteria, which show very high sensitivity and
low specificity (20), or the CERAD criteria alone. There is
evidence that the presence of neocortical NFTs is more
closely correlated with cognitive decline than the amyloid
plaque burden or distribution (21). This correlation was also
verified in the present study and in two other population-
based studies (22,23), in which the rates of neuropatholo-
gical AD in the non-demented groups were 9.6%, 7.4% (23),
and 21.9% (22), respectively, using the CERAD criteria plus
Braak stage, compared with 12.5%, 33.0% (23), and 54.8%
(22), respectively, using the CERAD criteria alone.
No generally accepted neuropathological criteria for VaD
have been established thus far, and each center has adopted
its own criteria. Even the nature of the cerebrovascular
lesions believed to cause cognitive decline varies consider-
ably (13,23). In addition, it is now clear that the amount of
brain destruction required to cause dementia is smaller than
was previously appreciated (13,25). We used conservative
criteria because only cases with large chronic infarcts or
lacunar or microinfarcts in strategic areas were diagnosed
with VaD. Had isolated, but widespread, SVD been
considered part of our criteria, the proportion of VaD
diagnosed in our series would have been even greater.
The proportion of individuals with LBD (4.4%), including
Parkinson’s disease and dementia with Lewy bodies, was
similar to that in some studies (12,15), although much
higher rates (more than 20%) have also been reported.
The high prevalence of VaD or AD plus VaD found in the
present study might reflect the limited access of the study
population to basic healthcare, particularly for arterial
hypertension and hypercholesterolemia, as well as poor
Table 3 - Clinical and neuropathological diagnoses of the dementia group (n = 113).
Clinical diagnoses Neuropathological diagnosis Total
AD VaD AD plus VaD Other dementias Undefined
AD 24 9 9 4 6 52 (46.0%)
VaD 5 5 3 5 2 20 (17.7%)
AD plus CVD 3 6 3 1 6 19 (16.8%)
Other dementias 4 1 0 3 1 9 (7.9%)
Undefined 4 3 0 3 3 13 (11.5%)
Total 40 (35.4%) 24 (21.2%) 15 (13.3%) 16 (14.2%) 18 (15.9%) 113 (100.0%)
AD: Alzheimer’s disease; CVD: cerebrovascular disease; VaD: vascular dementia.
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control of other risk factors for cerebrovascular disease and
vascular cognitive impairment (25). However, low educa-
tional level was not associated with a higher frequency of
VaD in this study, although we found that VaD was more
frequent in men. Additionally, in the younger individuals,
AD was more frequent in women, and AD associated with
VaD was more frequent in older individuals.
In addition, other factors might have contributed to the
high proportion of VaD. The Brazilian population is highly
mixed genetically, mainly due to historical waves of
immigration from Africa, Europe, and Asia. In a recent
genetic study, performed using a random sample of 202
BBBABSG cases, 102 (55.4%) had significant African
ancestry, and it was also shown that African ancestry might
be protective against AD neuropathology (26).
From a clinical standpoint, we detected relatively high
sensitivity and low specificity for the clinical diagnosis of
AD. High sensitivity and low specificity in the clinical
diagnosis of AD with the NINCDS-ADRDA criteria was
reported in a study that involved 31 US academic medical
centers (15). In contrast, we found low sensitivity and
relatively high specificity for the diagnosis of VaD (either
‘‘pure’’ or associated with other diseases). Low sensitivity of
the clinical criteria for VaD has been found in similar
population-based studies (27,28), particularly those using
the NINDS-AIREN criteria, the same criteria adopted in the
present study. These findings support the hypothesis that
the true frequency of VaD is greater than usually detected
clinically. In contrast, we and others have adopted
conservative neuropathological criteria for VaD (27), and
this choice could have contributed to the low sensitivity of
the clinical criteria.
Interestingly, SVD was detected more frequently in cases
with dementia than in the control group, even after
adjustment for age of death, sex, and education. It is also
noteworthy that SVD was frequently present in cases of
dementia with undefined pathological diagnoses, suggest-
ing that SVD might have been the neurobiological basis of
the cognitive loss. Microvascular injury, with no clear
parenchymal destruction, worsens cognition if present in
strategic regions (13). Indeed, in some brain samples from
individuals with dementia, microvascular injury has been as
common as Alzheimer-type pathology (8,13). Although
most of the published population-based clinicopathological
studies have not provided information on microvascular
injuries, evidence has shown that the burden of cerebral
amyloid angiopathy, a common finding in AD, is correlated
with white matter changes, suggesting that both processes
could share pathophysiological mechanisms (29).
More than one-third of our control group met the criteria
for neurodegenerative disease. The cause might have been
the high number of control subjects with argyrophilic grain
disease. Although these conditions seem to be rather
protective, or at least benign, in most of the cases (30), they
are still considered part of the neurodegenerative disease
spectrum (31). Neuropathological diagnoses were made
blinded to clinical status. The frequencies of AD and VaD in
the control group were similar to those reported in the
literature (32,33).
One limitation of the present study was the means of
sample procurement because death caused by cardiovas-
cular conditions was significantly more frequent in indivi-
duals who died after the age of 50 years old and who
underwent autopsy, compared with those who did undergo
an autopsy (data unpublished). This difference most likely
occurred because death caused by an acute event, such as
cardiac arrest, was more likely to require an autopsy. This
over-representation of cardiovascular conditions might
have increased the frequency of cerebrovascular lesions in
both groups (those with dementia and the controls), but it
should be emphasized that cerebrovascular lesions and SVD
were much more frequent in the group with dementia. In
contrast, individuals with acute stroke were excluded from
our study because cases with macroscopically detectable
acute brain infarctions, hemorrhages, or trauma could not
be included in the BBBABSG, as an immediate examination
was required for the completion of the death certificate. This
fact might have decreased the frequency of VaD in our
sample. Unfortunately, shortcomings in case selection have
been found in all the population-based studies on dementia.
For instance, 48% of the first 209 subjects submitted to
autopsy in the CFAS study had dementia, a much higher
proportion than the general population in this age group
(24), whereas the Honolulu study only recruited subjects of
Japanese ethnicity (34).
The absence of ante mortem examination of the cases
included in the present study was an obvious limitation. We
attempted to compensate for this limitation by using a semi-
structured protocol with several questionnaires and the
CDR scale, which were applied by trained interviewers to
informants who were close to the deceased study subjects
(9). The CDR scale is mostly an informant-based ques-
tionnaire, and a former study reported that informant CDR
scores showed good agreement with clinician CDR scores
(35). In addition to these precautions, we only included
cases with moderate or severe dementia (CDR$2) to reduce
the possibility of a misdiagnosis of dementia. In a previous
study (36), we prospectively compared the sensitivity and
specificity of our protocol applied to informants of living
patients with the diagnosis established in our memory
clinic, where the same patients were submitted to full
assessments. The sensitivity was 86.6%, and the specificity
was 84.4% for the diagnosis of dementia, but both reached
100% for cases with CDR$2. For the diagnosis of normal
cognition, the sensitivity was 65.3%, whereas the specificity
was 93.7%.
In conclusion, we postulate that the lack of appropriate
control of risk factors for circulatory diseases, combined
with the genetic particularities of our population, might
have been the main causes of the high prevalence of VaD,
AD plus VaD, and SVD in this sample. These factors might
also apply for other developing countries and even for
developed countries with high frequencies of VaD, particu-
larly in which the clinical control of vascular risk factors is
inadequate. Our findings are readily applicable to public
health initiatives because this high frequency of vascular
pathology could be preventable, and it represents a valuable
therapeutic target for postponing the onset of dementia,
thus decreasing its prevalence.
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